Lidocaine and the quarternary ammonium compound QX-572 in acute myocardial infarction. A comparative study.

Abstract

Patients with suspected or proven acute myocardial infarction complicated by ventricular arrhythmias not corrected by lidocaine therapy (bolus dose 100 mg followed by infusion 2 mg/min) were treated either with an increased dose of lidocaine (bolus dose 50 mg followed by infusion 3 mg/min) or with 600 mg N,N-bis dimethylammonium chloride (QX-572, Astra, Sweden) as an i.v. infusion during 30 min (3 patients) or 60 min (13 patients). In the lidocaine group the arrhythmias were controlled in 6 out of 15 patients, in the QZ-572 group in 12 out of 16, a difference that is not statistically significant. However, the frequency of side-effects was significantly higher (p less than 0.001) in the QX-572 group (15 out of 16 patients). They were also more severe, including pronounced tachycardia and hypertension. It is concluded that despite the high antiarrhythmic effect of QX-572, an increase of the lidocaine dose would be safer and preferable in the clinical situation studied.

• Authors: B Bergdahl, E Karlsson, J O Magnusson, C Sonnhag
• Journal: Acta medica Scandinavica (Acta Med Scand) Vol. 204 Issue 4 Pg. 311-4 ( 1978) ISSN: 0001-6101 [Print] Sweden
• PMID: 358766 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Anti-Arrhythmia Agents
• Quaternary Ammonium Compounds
• Lidocaine
• carcainium chloride

Topics

• Acute Disease
• Adult
• Aged
• Anti-Arrhythmia Agents (administration & dosage, adverse effects, therapeutic use)
• Arrhythmias, Cardiac (etiology, prevention & control)
• Clinical Trials as Topic
• Drug Evaluation
• Female
• Humans
• Infusions, Parenteral
• Lidocaine (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
• Male
• Middle Aged
• Myocardial Infarction (complications)
• Quaternary Ammonium Compounds (administration & dosage, adverse effects, therapeutic use)